Under a tenth of individuals eligible to benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it releases its inaugural advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer access to GLP-1 medication.
Per forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"Our latest guidelines recognises that excess weight is a long-term condition that can be addressed with thorough and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major barriers to universal availability to the treatments that can aid individuals in losing significant body mass, notes the organization.
Weight-Loss Drug Scarcity
Even under the present best projected outlook, the supply of these medications would only suffice for around 100 million people – less than 10% of the global need, according to the WHO.
The recommendation urges governments and firms to expand access, via strategies like patent sharing.
Exclusive production rights on the active ingredient – the core component of the drug Wegovy – is due to expire in several nations in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs imitate a natural hormone to reduce digestion speed, reduce hunger and enhance satiety so users reduce food intake.
People typically begin shedding pounds within a few weeks of starting on the weekly injections.
Studies suggests patients may put most of the weight back on after a year of discontinuing the medication, because their usual food cravings resume.
Being overweight or obese elevates your likelihood for contracting diseases, including type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
